IntegraGen announces miR-31-3p publication in Oncotarget

IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…)  » 

IntegraGen to attend 35th Annual JP Morgan Healthcare Conference

IntegraGen  will be in attendance at 35th Annual JP Morgan Healthcare Conference being held in San Francisco on January 9-12, 2017. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which brings together global industry leaders, emerging fast-growth companies, innovative (…)  »